The U.S. cell therapy raw materials market size was estimated at USD 2.06 billion in 2024 and is projected to reach USD 9.37 billion by 2033, growing at a CAGR of 18.42% from 2025 to 2033. Growth is driven by the rising number of cell therapy approvals, increasing demand for GMP-grade and high-quality inputs, and advancements in regenerative medicine. In addition, expanding biomanufacturing capabilities, increased funding, and the growing role of CDMOs in therapeutic development are further propelling the market forward, as the industry prioritizes reliable, scalable, and regulatory-compliant raw materials to support clinical and commercial cell therapy programs.
This demand is reflected in the expanding pipeline of cell and gene therapy candidates progressing through clinical trials. As seen in the accompanying table, therapies like Anito cel (Arcellx/Gilead) and OTL 203 (Orchard Therapeutics) are advancing through Phase II and III stages, targeting complex conditions such as multiple myeloma and Hurler syndrome. These trials, along with others in early and mid-development phases, illustrate the diversity of indications and technologies being pursued.
The development of such therapies relies heavily on specialized raw materials for reproducible and compliant manufacturing. As a result, strategic partnerships between therapy developers and raw material providers are becoming increasingly common, highlighting the foundational role of raw materials in supporting innovation and driving long-term growth across the U.S. cell therapy landscape.
This product will be delivered within 2 business days.
Expanding Therapy Pipelines Drive Demand for Components
The U.S. cell and gene therapy raw materials industry is experiencing strong growth, driven by the increasing number of personalized therapies and the complexity of their manufacturing processes. As cell therapies transition from research to commercialization, demand for high-grade raw materials-such as culture media, plasmid DNA, growth factors, and viral vectors-has surged. Developers seek products that offer consistency, scalability, and regulatory compliance to support both clinical and commercial-scale production. Moreover, rising investments, facility expansions, and technology upgrades by raw material suppliers have further accelerated market momentum, strengthening the infrastructure supporting advanced therapy development.This demand is reflected in the expanding pipeline of cell and gene therapy candidates progressing through clinical trials. As seen in the accompanying table, therapies like Anito cel (Arcellx/Gilead) and OTL 203 (Orchard Therapeutics) are advancing through Phase II and III stages, targeting complex conditions such as multiple myeloma and Hurler syndrome. These trials, along with others in early and mid-development phases, illustrate the diversity of indications and technologies being pursued.
The development of such therapies relies heavily on specialized raw materials for reproducible and compliant manufacturing. As a result, strategic partnerships between therapy developers and raw material providers are becoming increasingly common, highlighting the foundational role of raw materials in supporting innovation and driving long-term growth across the U.S. cell therapy landscape.
U.S. Cell Therapy Raw Materials Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. The analyst has segmented the U.S. cell therapy raw materials market report based on the product, and end use:Product Scope Outlook (Revenue, USD Million, 2021-2033)
- Media
- Sera
- Cell Culture Supplements
- Antibodies
- Reagents & Buffers
- Others
End Use Scope Outlook (Revenue, USD Million, 2021-2033)
- Biopharmaceutical & Pharmaceutical Companies
- CROs & CMOs
- Others
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the industry across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segmental and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Market Variables, Trends, & Scope
Chapter 4. Product Business Analysis
Chapter 5. End-use Business Analysis
Chapter 6. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies profiled in this U.S. Cell Therapy Raw Materials market report include:- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher
- Sartorius Stedim Biotech
- Actylis.
- ACROBiosystems
- STEMCELL Technologies.
- Grifols, S.A.
- Charles River Laboratories
- RoosterBio, Inc.
- PromoCell GmbH
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 90 |
| Published | August 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 2.06 Billion |
| Forecasted Market Value ( USD | $ 9.37 Billion |
| Compound Annual Growth Rate | 18.4% |
| Regions Covered | United States |
| No. of Companies Mentioned | 12 |
